Search by Drug Name or NDC
NDC 00003-4040-12 Augtyro 40 mg/1 Details
Augtyro 40 mg/1
Augtyro is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by E.R. Squibb & Sons, L.L.C.. The primary component is REPOTRECTINIB.
MedlinePlus Drug Summary
Repotrectinib is used to treat a certain type of non-small cell lung cancer (NSCLC; a type of lung cancer) in adults that has spread to other parts of the body. Repotrectinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
Related Packages: 00003-4040-12Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Repotrectinib
Product Information
| NDC | 00003-4040 |
|---|---|
| Product ID | 0003-4040_fb526827-40ba-4462-94cf-179ae3b0cb8a |
| Associated GPIs | |
| GCN Sequence Number | 085515 |
| GCN Sequence Number Description | repotrectinib CAPSULE 40 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 55019 |
| HICL Sequence Number | 049312 |
| HICL Sequence Number Description | REPOTRECTINIB |
| Brand/Generic | Brand |
| Proprietary Name | Augtyro |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | repotrectinib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 40 |
| Active Ingredient Units | mg/1 |
| Substance Name | REPOTRECTINIB |
| Labeler Name | E.R. Squibb & Sons, L.L.C. |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA218213 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00003-4040-12 (00003404012)
| NDC Package Code | 0003-4040-12 |
|---|---|
| Billing NDC | 00003404012 |
| Package | 120 CAPSULE in 1 BOTTLE (0003-4040-12) |
| Marketing Start Date | 2023-12-05 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |